A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness

计划入组 1,755 人 · 首次发布于 2020 年 11 月 18 日

BLAZE-Limiting Approach in NMOSD

计划入组 9 人 · 首次发布于 2025 年 3 月 21 日

Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)

计划入组 10 人 · 首次发布于 2025 年 9 月 23 日

TfR1(Blaze)

Terpinen-4-ol

C₁₀H₁₈O

BE-4-4-4-4

Blaze Bioscience, Inc.

United States

Xi'an No.4 Hospital

China

BLAZE BIOSCIENCE AUSTRALIA PTY LTD

Australia

FDA Grants Emergency Authorization to Lilly's Bebtelovimab for COVID-19, Securing $720M Government Contract

Faron Launches BLAZE Trial with ICR to Test Novel Approach for Overcoming Immunotherapy Resistance

Faron Updates Bexmarilimab IIT Portfolio: BLAZE Switches to Nivolumab, BEXAR Cleared in Sarcoma, FINPROVE Cohort Discontinued